~~<i id='934AE8C4FC'><strike id='934AE8C4FC'><tt id='934AE8C4FC'><pre id='934AE8C4FC'></pre></tt></strike></i>~~

Home» comprehensive» Wikipedia

Wikipedia

author：leisure time 2025-08-26 04:52:55 Page View：2499

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： David Ricks of Eli Lilly: best biopharma CEO of 2023
Next article： Heart attack and stroke risk calculators need revising

explore

Tori Bowie and the unacceptable rates of Black maternal death

AlastairGrant/APThehorrorstoriesofBlackwomendyingorcomingclosetodeathinchildbirthneverseemtostopcomi

Can sheer will power keep patients alive in their dying hours?

ArmellaLeungforSTATMarjorieSeverancehadlived91years,fivemonths,andtwoweekswhen,ifyoubelievesuchthing

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

Why depression after traumatic brain injury is distinct

AdobeTraumaticbraininjurymultipliestheriskofmajordepressioneightfold.Whiletheemotionaltraumaofwhatev